Tandem Diabetes Care (Nasdaq:TNDM) shares got a boost after hours today on third-quarter results that came in ahead of the consensus forecast.
Shares of TNDM rose nearly 20% to $15.89 apiece in post-market trading today.
The San Diego-based automated insulin delivery technology developer reported losses of $21.2 million. That equals 31¢ per share on sales of $249.3 million for the three months ended Sept. 30, 2025.
Tandem — one of the largest diabetes tech companies in the world — recorded a 9% bottom-line gain on a sales increase of 2.2%. The company said its third-quarter sales marked records for both the U.S. and internationally.
Losses per share landed 3¢ ahead of expectations on Wall Street. Sales also topped estimates as experts projected $235.8 million in revenue.
https://www.massdevice.com/tandem-stock-rises-after-hours-on-q3-beats-record-sales/
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.